🔗 Share this article

While America proceeds with sweeping revisions to its immunization guidelines, an unexpected name has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by casting doubt on coronavirus shots in the global health crisis and has focused upon alleged fatalities after Covid vaccination in her short position at the US Food and Drug Administration (FDA).

Proposed Changes to Pediatric Vaccine Schedule

Agency leaders were set to reveal major changes to the pediatric vaccine schedule recently, bringing the US with Denmark’s national calendar, sources say – a significant shift that would put the US out of step with many the global community with no evidence for benefit. The announcement has been pushed back until the coming year.

In place of the top vaccines chief, Tracy Beth Høeg is set to address the audience at the event. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the division this year.

A Shift at the FDA

The acting appointment might represent a tighter collaboration between the drug and vaccine centers as Høeg and Prasad solidify control at the regulatory agency – and it signals a increased emphasis upon rolling back previously authorized immunizations at the FDA.

Høeg has often pushed for discontinuing certain childhood immunization guidelines in the US so as to align more similar to Denmark, a society with universal health coverage and a population about the size of Wisconsin’s.

In her initial statements, she has continued to focus on vaccination policy – traditionally the responsibility of Dr. Prasad, director of the FDA’s CBER – rather than pharmaceutical oversight.

Questions Over Background

The appointee has no obvious background in drug development, regulation or leadership, which has been standard for former directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the commissioner and CBER since earlier this year.

“It seems she lacks to have any of the qualifications” for running the drug-regulation department, stated Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in managing a major agency. She lacks background in drug approvals.”

Previous directors of the center would “understand laws and regulations and the research of medication creation”, noted a former acting FDA commissioner. “Clearly, she lacks the sort of resume that previous people who headed CBER have had.”

CDER has an vast portfolio at the FDA, the former commissioner pointed out.

“The public just focuses on the new drug program, but the generic drug division clears a multitude of generic drugs. There is also a biosimilars program, over-the-counter program and so forth, and every single one have to be supervised,” she explained. “The thing you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

There is also, a major leadership aspect to the job, which supervises more than 5,000 personnel. “It is a enormous administrative position, if you execute it properly,” Woodcock said.

Official Statement and Controversial Initiatives

Regarding concerns about Høeg’s fitness for the role and whether this appointment signifies greater collaboration among regulatory chiefs on vaccines, a press secretary said that the “concerns are based on incorrect presumptions”.

“Her experience is consistent with the functions of her role,” the official explained, noting the months Høeg spent guiding the agency head on “pharmaceutical safety and approval science, including computational safety modeling and immunization monitoring”.

As acting director, Dr. Høeg takes over the commissioner’s controversial expedited review system, a contentious rapid therapy clearance system that allegedly concerned her former heads. “How are these therapies being selected for this fast-track system? Who takes the calls?” Howard questioned. “There is a lot of lack of transparency going on at the agency right now.”

Broadly speaking, he stated, “the Food and Drug Administration looks to be trending towards laxer oversight of all drugs, with the exception of immunizations.”

Documented History on Vaccines

With vaccines, Dr. Høeg has a clearer, if problematic, history, some experts observe. She released a analysis using unconfirmed volunteer-provided data to assess the incidence of myocarditis following Covid immunization. She advised the state of Florida top health official Dr. Joseph Ladapo, who was said to have changed statistics to indicate Covid vaccinations are pose a greater threat than they are.

Included in her “wish list” for the current federal leadership encompassed altering guidelines for novel immunizations and ending “non-essential” vaccines, she said following the vote on a online show. At the agency, Dr. Høeg has reportedly suggested barring adolescent males from receiving Covid vaccines.

“She’s an complete true believer who begins with her preconceived notions and tailors the evidence to accommodate the data in a highly misleading, fraudulent fashion,” Dr. Howard argued.

Taking Control and a “Revenge Tour”

Dr. Høeg aligned with fellow skeptics, {like|